Greatbatch (GB) Issues Light FY16 Revenue Outlook

Greatbatch, Inc. (NYSE: GB) provided preliminary 2015 revenue and guidance for 2016. Greatbatch President and Chief Executive Officer, Thomas J. Hook, will provide further details and discuss the company’s strategy for long-term growth and profitability during meetings at the 34th annual J.P. Morgan Healthcare Conference in San Francisco.

In 2016, Greatbatch expects:

• Margin Expansion
  • Leverage global operations footprint to improve our cost competitiveness while meeting the highest quality standards
• Organic Growth
  • Drive incremental sales in core product lines through current customers and enrolling new customers
  • Expand capabilities to create complete devices and systems in other markets across Greatbatch portfolio
• Nuvectra spinoff
  • Opportunity for shareholders to acquire Nuvectra shares in a tax free transaction

The company’s guidance update is as follows:

*** The Street sees FY15 revenue at $822 million and FY16 revenue at $1.55 billion.

(1) Pro forma for Lake Region merger and Nuvectra spinoff. 2015 Sales results are preliminary and subject to revision.

(2) Our full year 2015 and 2016 Adjusted EBITDA guidance consists of estimated GAAP net income plus estimates of i) interest expense, ii) taxes, iii) depreciation, iv) amortization of intangible assets, v) inventory step-up amortization, vi) IP related litigation charges, vii) stock-based compensation, viii) consolidation costs, ix) acquisition and integration costs, x) asset write-offs and severance, xi) debt extinguishment charges, and xii) non-cash gains/losses on investments. These amounts are not yet available for 2015 and 2016 and will be provided by the Company when available.

Greatbatch presentation and historical pro forma information can be found on the company’s website www.greatbatch.com.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Universe Pharmaceuticals to acquire five-patent portfolio for $10.75M
• TNL Mediagene faces Nasdaq delisting over bid price and equity rules